Navigation Links
BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
Date:9/4/2008

otide (MBP8298)

--------------------------

Dirucotide (MBP8298) is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). Dirucotide is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of dirucotide is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients.

The drug's apparent mechanism of action is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide periodically delivered intravenously. The potential benefit of the drug for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, dirucotide (MBP8298), if approved, has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

Dirucotide (MBP8298) is being studied in four late-stage clinical trials:

- MAESTRO-01: A pivotal phase II/III trial for secondary progressive MS

(SPMS) patients in Canada and Europe.

- MAESTRO-02: An open-label safety extension study to MAESTRO-01.

- MAESTRO-03: A pivotal phase III trial for SPMS patients
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. BioMS Medical Announces Second Quarter 2008 Results
4. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
5. BioMS Medical to present at BMO Healthcare Conference
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medical to present at Jefferies Healthcare Conference
8. BioMS Medical to present at 2008 BIO International Convention
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical announces first quarter 2008 results
11. BioMs Medical to present at TIDES(R) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Mass. , Feb. 27, 2015 ... of the NCATS rare-diseases portfolio " in ... a new financing technique to reduce the risk ... diseases and potentially unlock new levels of funding ... The product of a unique collaboration between scientists ...
(Date:2/27/2015)... 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), a ... therapeutics, today announced that it will be presenting at ... March 2 nd at 3pm PST. Patrick Lucy, chief ... discussing the current state of the biosimilar industry landscape ... For more information on CALBIO 2015 and ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)... 2015   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... Chief Executive Officer of Regulus, will present a company ... Annual Healthcare Conference on Wednesday, March 4, 2015 at ... the Boston Marriott Copley Place.  The ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... differences among countries. This is what medical researchers ... from biobanks in their research. For one thing, ... international studies. In the latest issue of Nature ... (CBE), together with leading biobank researchers, put forward a ...
... of disease is often critical to how successful treatment can ... is a hot research field, where every small step is ... issue of Molecular & Cellular Proteomics, Uppsala University researchers describe ... Proteins build up the bodys cells and tissues, and our ...
... Washington DC*-- Key components of a new approach to ... Friday as part of a twelve-day, low-Earth orbit experiment ... prelude future journeys to Mars. , The new approach ... pregnancy test kits. The so-called immunoassays are embodied in ...
Cached Biology Technology:Long-awaited international ethical guidelines for biobank researchers 2Life on Mars 'pregnancy test' successfully launched 2
(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... by researchers at Hasbro Childrens Hospital, the pediatric division ... York, offers new insight into the role that the ... disease. The cystic fibrosis transmembrane conductance regulator (CFTR) ... Mutations of this protein are associated with cystic fibrosis ...
... which tend to involve localized changes in sea surface ... than the more uniform patterns of global warming, a ... debate over the effect of global warming on hurricanes, ... more favorable environment for hurricane development and intensification. However, ...
... Viejo, California) Ossur, an emerging leader in the ... of integration, is pleased to announce that the Journal ... two year cervical collar study performed by the Mayo ... Interface Pressure from Four Cervical Collars, finds that Ossurs ...
Cached Biology News:Study uncovers clues to cystic fibrosis gene dysfunction and gastrointestinal disease 2Climate's remote control on hurricanes 2Mayo Clinic study: Ossur's collars superior in immobilization and reduction of pressure 2